Bain Capital is in talks to acquire Mitsubishi Chemical Group’s pharmaceutical business in a potential multibillion-dollar ...

Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience ...

Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital ...

Of the 24 drugs, three approvals deviated from the others -- aducanumab; the synthetic hormone hydroxyprogesterone caproate ...

Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...

A series of disappointments that drove Sage Therapeutics Inc.’s stock down by 85% since August of 2023 has evolved into an unsolicited takeout offer by partner Biogen Inc., followed by a lawsuit filed ...

The biopharmaceutical industry is aiming for a 2025 reversal of last year's slump in investor returns but remains wary over ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Billionaire investor Ken Griffin is the founder of Citadel Advisors, one of the world’s most successful alternative ...

Discover the latest advancements in gene therapy for rare diseases like Friedreich's Ataxia and Duchenne Muscular Dystrophy, ...

Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...